C Arnold Spek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3424652/publications.pdf

Version: 2024-02-01

196 papers	5,834 citations	66343 42 h-index	98798 67 g-index
200 all docs	200 docs citations	200 times ranked	7126 citing authors

#	Article	IF	Citations
1	Repression of Smoothened by Patched-Dependent (Pro-)Vitamin D3 Secretion. PLoS Biology, 2006, 4, e232.	5.6	260
2	Nuclear Receptors Nur77, Nurr1, and NOR-1 Expressed in Atherosclerotic Lesion Macrophages Reduce Lipid Loading and Inflammatory Responses. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2288-2288.	2.4	213
3	The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood, 2000, 96, 554-559.	1.4	192
4	Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends in Molecular Medicine, 2008, 14, 429-440.	6.7	158
5	Antiinflammatory Effects of Salmeterol after Inhalation of Lipopolysaccharide by Healthy Volunteers. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 878-884.	5.6	142
6	Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Research, 2003, 31, 153e-153.	14.5	139
7	Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19497-19502.	7.1	139
8	Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene, 2010, 29, 6314-6322.	5.9	129
9	Factor Xa Stimulates Proinflammatory and Profibrotic Responses in Fibroblasts via Protease-Activated Receptor-2 Activation. American Journal of Pathology, 2008, 172, 309-320.	3.8	116
10	Genotypic Variation in the Promoter Region of the Protein C Gene Is Associated With Plasma Protein C Levels and Thrombotic Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 214-218.	2.4	105
11	Tissue Factor and Cancer Metastasis: The Role of Intracellular and Extracellular Signaling Pathways. Molecular Medicine, 2004, 10, 6-11.	4.4	97
12	Hedgehog: an unusual signal transducer. BioEssays, 2004, 26, 387-394.	2.5	97
13	Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene, 2004, 23, 410-417.	5.9	95
14	Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia*. Critical Care Medicine, 2006, 34, 1725-1730.	0.9	93
15	Sonic hedgehog induces transcription-independent cytoskeletal rearrangement and migration regulated by arachidonate metabolites. Cellular Signalling, 2007, 19, 2596-2604.	3.6	92
16	The Pleiotropic Effects of Tissue Factor: a Possible Role for Factor VIIa-induced Intracellular Signalling?. Thrombosis and Haemostasis, 2001, 86, 1353-1359.	3.4	84
17	Hypoxia induces a hedgehog response mediated by HIFâ€1Î±. Journal of Cellular and Molecular Medicine, 2009, 13, 2053-2060.	3.6	83
18	mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome. Journal of Clinical Oncology, 2011, 29, e150-e153.	1.6	78

#	Article	IF	Citations
19	Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1â€“mediated vascular endothelial barrier enhancement. Blood, 2009, 114, 1968-1973.	1.4	76
20	Activated Protein C Protects Against Myocardial Ischemia/ Reperfusion Injury via Inhibition of Apoptosis and Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1087-1092.	2.4	73
21	Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation*. Critical Care Medicine, 2005, 33, 1365-1370.	0.9	72
22	Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood, 2011, 118, 2889-2895.	1.4	68
23	Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood, 2007, 110, 3176-3182.	1.4	65
24	Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department. Critical Care Medicine, 2010, 38, 457-463.	0.9	61
25	Microvascular coagulopathy and disseminated intravascular coagulation. Critical Care Medicine, 2001, 29, S95-S97.	0.9	60
26	Disseminated intravascular coagulation. The Hematology Journal, 2003, 4, 295-302.	1.4	60
27	Tissue factor signal transduction in angiogenesis. Carcinogenesis, 2003, 24, 1009-1013.	2.8	58
28	Proteaseâ€activated receptorâ€1 drives pancreatic cancer progression and chemoresistance. International Journal of Cancer, 2014, 135, 2294-2304.	5.1	58
29	Blood coagulation factors as inflammatory mediators. Blood Cells, Molecules, and Diseases, 2005, 34, 30-37.	1.4	56
30	Protease-Activated Receptor-2 Induces Myofibroblast Differentiation and Tissue Factor Up-Regulation during Bleomycin-Induced Lung Injury. American Journal of Pathology, 2010, 177, 2753-2764.	3.8	55
31	Treatment with an anti-CD14 monoclonal antibody delays and inhibits lipopolysaccharide-induced gene expression in humans in vivo. Journal of Clinical Immunology, 2003, 23, 132-140.	3.8	53
32	Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohnâ€™s disease patients. Journal of Molecular Medicine, 2005, 83, 601-609.	3.9	53
33	Toll-like receptor mRNA levels in alveolar macrophages after inhalation of endotoxin. European Respiratory Journal, 2006, 28, 622-626.	6.7	53
34	Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?. Journal of Cellular and Molecular Medicine, 2012, 16, 2035-2048.	3.6	52
35	Inhibition of the Tissue Factor/Factor VIIa Pathway Does Not Influence the Inflammatory or Antibacterial Response to Abdominal Sepsis Induced byEscherichia coliin Mice. Journal of Infectious Diseases, 2004, 189, 2308-2317.	4.0	50
36	FVIIa:TF Induces Cell Survival via G12/G13-Dependent Jak/STAT Activation and BclXLProduction. Circulation Research, 2004, 94, 1032-1040.	4.5	50

#	Article	IF	Citations
37	Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. Journal of Cellular and Molecular Medicine, 2008, 12, 2622-2627.	3.6	49
38	Promoter analysis of the auxin-regulated tobacco glutathione S-transferase genes Nt103-1 and Nt103-35. Plant Molecular Biology, 1995, 29, 413-429.	3.9	47
39	Human Plasma Very Low Density Lipoprotein Carries Indian Hedgehog. Journal of Proteome Research, 2010, 9, 6052-6059.	3.7	47
40	Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?. Biology, 2020, 9, 80.	2.8	45
41	Differential Gene Expression Changes in Children with Severe Dengue Virus Infections. PLoS Neglected Tropical Diseases, 2008, 2, e215.	3.0	45
42	Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. British Journal of Pharmacology, 2006, 149, 740-746.	5.4	44
43	Hedgehog Morphogen in Cardiovascular Disease. Circulation, 2006, 114, 1985-1991.	1.6	44
44	Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis. Thorax, 2014, 69, 152-160.	5.6	44
45	Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites. Journal of Biological Chemistry, 1995, 270, 24216-24221.	3.4	43
46	Targeting coagulation factor receptors â€“ proteaseâ€activated receptors in idiopathic pulmonary fibrosis. Journal of Thrombosis and Haemostasis, 2017, 15, 597-607.	3.8	42
47	Violacein Induces Death of Resistant Leukaemia Cells via Kinome Reprogramming, Endoplasmic Reticulum Stress and Golgi Apparatus Collapse. PLoS ONE, 2012, 7, e45362.	2.5	42
48	Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice*. Critical Care Medicine, 2006, 34, 2201-2206.	0.9	41
49	Gross deletions/duplications in PROS1 are relatively common in point mutation-negative hereditary protein S deficiency. Human Genetics, 2009, 126, 449-456.	3.8	41
50	Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Research and Therapy, 2010, 7, 9.	1.7	40
51	PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex. Scientific Reports, 2015, 5, 14534.	3.3	40
52	Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation. Cellular Oncology (Dordrecht), 2020, 43, 1161-1174.	4.4	40
53	Effects of IC14, an Antiâ€CD14 Antibody, on Coagulation and Fibrinolysis during Lowâ€Grade Endotoxemia in Humans. Journal of Infectious Diseases, 2003, 187, 55-61.	4.0	39
54	Active site inhibited factor VIIa attenuates myocardial ischemia/reperfusion injury in mice. Journal of Thrombosis and Haemostasis, 2009, 7, 290-298.	3.8	38

#	Article	IF	Citations
55	Endogenous Hedgehog Expression Contributes to Myocardial Ischemia-Reperfusionâ€“Induced Injury. Experimental Biology and Medicine, 2008, 233, 989-996.	2.4	36
56	C-Reactive Protein Elicits White Blood Cell Activation in Humans. American Journal of Medicine, 2009, 122, 582.e1-582.e9.	1.5	34
57	Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice. Scientific Reports, 2016, 6, 33030.	3.3	34
58	Proteaseâ€activated receptorâ€2 induces migration of pancreatic cancer cells in an extracellular ATPâ€dependent manner. Journal of Thrombosis and Haemostasis, 2013, 11, 1892-1902.	3.8	33
59	Proteaseâ€activated receptorâ€1 contributes to renal injury and interstitial fibrosis during chronic obstructive nephropathy. Journal of Cellular and Molecular Medicine, 2019, 23, 1268-1279.	3.6	33
60	PTX3 predicts severe disease in febrile patients at the emergency department. Journal of Infection, 2010, 60, 122-127.	3.3	32
61	Assessing the efficacy of the Hedgehog pathway inhibitor vitamin D3 in a murine xenograft model for pancreatic cancer. Cancer Biology and Therapy, 2010, 10, 79-88.	3.4	32
62	CCAAT/enhancer-binding protein Î´ facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9113-9118.	7.1	31
63	Irradiated Riboflavin Diminishes the Aggressiveness of Melanoma In Vitro and In Vivo. PLoS ONE, 2013, 8, e54269.	2.5	31
64	Type I Protein C Deficiency Caused by Disruption of a Hepatocyte Nuclear Factor (HNF)-6/HNF-1 Binding Site in the Human Protein C Gene Promoter. Journal of Biological Chemistry, 1998, 273, 10168-10173.	3.4	30
65	Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?. Journal of Clinical Medicine, 2019, 8, 1547.	2.4	30
66	Leukotriene Synthesis Is Required for Hedgehog-Dependent Neurite Projection in Neuralized Embryoid Bodies but Not for Motor Neuron Differentiation. Stem Cells, 2008, 26, 1138-1145.	3.2	29
67	Blood coagulation factor Xa as an emerging drug target. Expert Opinion on Therapeutic Targets, 2011, 15, 341-349.	3.4	29
68	Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung. Clinical and Experimental Metastasis, 2009, 26, 171-178.	3.3	28
69	Characterization of coagulation factor synthesis in nine human primary cell types. Scientific Reports, 2012, 2, 787.	3.3	28
70	High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells. Blood, 2005, 105, 2000-2006.	1.4	26
71	Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation. Experimental Cell Research, 2007, 313, 2622-2633.	2.6	25
72	The coagulation factor Xa/protease activated receptorâ€2 axis in the progression of liver fibrosis: a multifaceted paradigm. Journal of Cellular and Molecular Medicine, 2010, 14, 143-153.	3.6	25

#	Article	IF	Citations
73	PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer. Oncotarget, 2018, 9, 32010-32023.	1.8	25
74	Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation. Thrombosis Research, 2010, 125, e323-e328.	1.7	24
75	Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors. Drug Resistance Updates, 2012, 15, 211-222.	14.4	24
76	Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis. Molecular Medicine, 2015, 21, 576-583.	4.4	24
77	Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells. Thrombosis and Haemostasis, 2006, 96, 789-793.	3.4	23
78	Low dose endotoxin priming is accountable for coagulation abnormalities and organ damage observed in the Shwartzman reaction. A comparison between a single-dose endotoxemia model and a double-hit endotoxin-induced Shwartzman reaction. Thrombosis Journal, 2006, 4, 13.	2.1	23
79	Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease?. Trends in Pharmacological Sciences, 2009, 30, 8-16.	8.7	23
80	Lipid droplets hypertrophy: a crucial determining factor in insulin regulation by adipocytes. Scientific Reports, 2015, 5, 8816.	3.3	23
81	Proteaseâ€activated receptor (<scp>PAR</scp>)â€2 is required for <scp>PAR</scp>â€1 signalling in pulmonary fibrosis. Journal of Cellular and Molecular Medicine, 2015, 19, 1346-1356.	3.6	21
82	Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-Î± secretion. BMC Cancer, 2020, 20, 1183.	2.6	21
83	The Role of Coagulation in Chronic Inflammatory Disorders: A Jack of All Trades. Current Pharmaceutical Design, 2011, 17, 9-16.	1.9	20
84	Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis. Oncotarget, 2015, 6, 35304-35314.	1.8	20
85	Functional thrombomodulin deficiency causes enhanced thrombus growth in a murine model of carotid artery thrombosis. Basic Research in Cardiology, 2003, 98, 347-352.	5.9	19
86	Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation. Thrombosis Research, 2009, 124, 219-225.	1.7	19
87	Protease Activated Receptor-1 Deficiency Diminishes Bleomycin-Induced Skin Fibrosis. Molecular Medicine, 2014, 20, 410-416.	4.4	18
88	CCAAT-Enhancer Binding Protein Delta (C/EBPÎ´) Protects Against Klebsiella pneumoniaeâ€“Induced Pulmonary Infection: Potential Role for Macrophage Migration. Journal of Infectious Diseases, 2012, 206, 1826-1835.	4.0	17
89	Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. Journal of Pathology, 2014, 234, 398-409.	4.5	17
90	Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?. Thrombosis and Haemostasis, 2015, 114, 530-536.	3.4	17

#	Article	IF	Citations
91	Dabigatran Potentiates Gemcitabine-Induced Growth Inhibition of Pancreatic Cancer in Mice. Molecular Medicine, 2017, 23, 13-23.	4.4	17
92	Smoothened-dependent and -independent pathways in mammalian noncanonical Hedgehog signaling. Journal of Biological Chemistry, 2019, 294, 9787-9798.	3.4	17
93	A comparative Analysis by SAGE of Gene Expression Profiles of Esophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma. Analytical Cellular Pathology, 2008, 30, 63-75.	1.4	17
94	Genetic Risk Factors for Venous Thrombosis. Molecular Genetics and Metabolism, 2000, 71, 51-61.	1.1	16
95	Gene Expression Profiling Identifies C/EBPÎ´ as a Candidate Regulator of Endotoxin-induced Disseminated Intravascular Coagulation. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 602-609.	5.6	16
96	Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation. Cancer Letters, 2011, 306, 106-110.	7.2	16
97	The protein C pathway in cancer metastasis. Thrombosis Research, 2012, 129, S80-S84.	1.7	16
98	Protease-Activated Receptor (PAR)2, but Not PAR1, Is Involved in Collateral Formation and Anti-Inflammatory Monocyte Polarization in a Mouse Hind Limb Ischemia Model. PLoS ONE, 2013, 8, e61923.	2.5	16
99	Blood cell-derived tissue factor influences host response during murine endotoxemia. Blood Cells, Molecules, and Diseases, 2004, 32, 325-333.	1.4	15
100	Longâ€term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis. Journal of Thrombosis and Haemostasis, 2009, 7, 1595-1597.	3.8	15
101	CCAAT-enhancer binding protein delta (C/EBPÎ´) attenuates tubular injury and tubulointerstitial fibrogenesis during chronic obstructive nephropathy. Laboratory Investigation, 2014, 94, 89-97.	3.7	15
102	CEBPD Potentiates the Macrophage Inflammatory Response but CEBPD Knock-Out Macrophages Fail to Identify CEBPD-Dependent Pro-Inflammatory Transcriptional Programs. Cells, 2021, 10, 2233.	4.1	15
103	Regulation of the p21Ras-MAP kinase pathway by factor VIIa. Journal of Thrombosis and Haemostasis, 2003, 1, 1012-1018.	3.8	14
104	Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. Journal of Thrombosis and Haemostasis, 2004, 2, 2185-2193.	3.8	14
105	Tissue factor. Blood Coagulation and Fibrinolysis, 2004, 15, S3-S10.	1.0	14
106	(Pro-)vitamin D as treatment option for hedgehog-related malignancies. Medical Hypotheses, 2008, 70, 202-203.	1.5	14
107	TF:FVIIaâ€specific activation of CREB upregulates proapoptotic proteins via proteaseâ€activated receptorâ€2. Journal of Thrombosis and Haemostasis, 2008, 6, 1550-1557.	3.8	13
108	Tissue Factor-Dependent Chemokine Production Aggravates Experimental Colitis. Molecular Medicine, 2011, 17, 1119-1126.	4.4	13

#	Article	IF	Citations
109	The Acute-phase Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia â€“ A Prospective Cohort Study. Journal of Rheumatology, 2012, 39, 1914-1917.	2.0	13
110	High endogenous activated protein C levels attenuates bleomycinâ€induced pulmonary fibrosis. Journal of Cellular and Molecular Medicine, 2016, 20, 2029-2035.	3.6	13
111	Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells. Thrombosis and Haemostasis, 2006, 96, 789-93.	3.4	13
112	Protease-Activated Receptors, Apoptosis and Tumor Growth. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 137-147.	0.3	12
113	Colon cancer metastasis in mouse liver is not affected by hypercoagulability due to Factor V Leiden mutation. Journal of Cellular and Molecular Medicine, 2007, 11, 561-568.	3.6	12
114	Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2009, 68, 1654-1654.	0.9	12
115	FXa-induced intracellular signaling links coagulation to neoangiogenesis: Potential implications for fibrosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 798-805.	4.1	12
116	The Hedgehog morphogen in myocardial ischemiaâ€“reperfusion injury. Experimental Biology and Medicine, 2010, 235, 447-454.	2.4	12
117	The role of activated protein C in cancer progression. Thrombosis Research, 2010, 125, S138-S142.	1.7	12
118	Dichotomy in Hedgehog Signaling between Human Healthy Vessel and Atherosclerotic Plaques. Molecular Medicine, 2012, 18, 1122-1127.	4.4	12
119	Signal transduction induced by activated protein C: no role in protection against sepsis?. Trends in Molecular Medicine, 2006, 12, 374-381.	6.7	11
120	Protease-Activated Receptor 2 Facilitates Bacterial Dissemination in Pneumococcal Pneumonia. Journal of Infectious Diseases, 2018, 217, 1462-1471.	4.0	11
121	CCAAT/Enhancer-Binding Protein Delta (C/EBPÎ´): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcinoma Cells. Cancers, 2020, 12, 2546.	3.7	11
122	ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer. Cancers, 2021, 13, 3321.	3.7	11
123	A Low Molecular Weight Heparin Inhibits Experimental Metastasis in Mice Independently of the Endothelial Glycocalyx. PLoS ONE, 2010, 5, e11200.	2.5	11
124	Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview. Pharmaceutics, 2022, 14, 390.	4.5	11
125	In silico tissue factor analysis: a bit-to-bit comparison. Thrombosis and Haemostasis, 2003, 89, 592-593.	3.4	10
126	Role of coagulation FVIII in septic peritonitis assessed in hemophilic mice. Journal of Thrombosis and Haemostasis, 2005, 3, 2738-2744.	3.8	10

#	Article	IF	Citations
127	Alternatively spliced tissue factor in mice: induction by Streptococcus pneumoniae. Journal of Thrombosis and Haemostasis, 2006, 4, 918-920.	3.8	10
128	Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer. BMC Cancer, 2017, 17, 113.	2.6	10
129	Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer. Thrombosis Research, 2017, 154, 1-6.	1.7	10
130	Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice. Oncotarget, 2018, 9, 21655-21662.	1.8	10
131	Hyperglycemia accelerates arterial thrombus formation and attenuates the antithrombotic response to endotoxin in mice. Blood Coagulation and Fibrinolysis, 2007, 18, 627-636.	1.0	9
132	Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma. Carcinogenesis, 2019, 40, 155-163.	2.8	9
133	Cathepsin S Contributes to Lung Inflammation in Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 769-782.	5.6	9
134	A dual role for 7-dehydrocholesterol reductase in regulating Hedgehog signalling?. Development (Cambridge), 2006, 133, 3951-3951.	2.5	8
135	Factor V Leiden and the etiology of inflammatory bowel disease. Thrombosis and Haemostasis, 2007, 98, 670-673.	3.4	8
136	Identification of Evolutionarily Invariant Sequences in the Protein C Gene Promoter. Journal of Molecular Evolution, 1998, 47, 663-669.	1.8	7
137	Gene Expression Profiles in Murine Influenza Pneumonia. Journal of Innate Immunity, 2009, 1, 366-375.	3.8	7
138	Plasmin reduces fibronectin deposition by mesangial cells in a protease-activated receptor-1 independent manner. Biochemistry and Biophysics Reports, 2017, 10, 152-156.	1.3	7
139	Pharmacological PARâ€1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy. FASEB Journal, 2019, 33, 10966-10972.	0.5	7
140	Is idiopathic pulmonary fibrosis a cancer-like disease? Transcriptome analysis to fuel the debate. ERJ Open Research, 2019, 5, 00157-2018.	2.6	7
141	Hedgehog Turns Lipoproteins Into Janus-Faced Particles. Trends in Cardiovascular Medicine, 2006, 16, 217-220.	4.9	6
142	High factor VIIa levels do not promote tumor metastasis. Thrombosis and Haemostasis, 2008, 99, 787-788.	3.4	6
143	Protease-activated receptor-4 deficiency does not protect against bleomycin-induced pulmonary fibrosis in mice: Figure 1â€“. European Respiratory Journal, 2012, 40, 1056-1057.	6.7	6
144	The Effect of Levothyroxine on Expression of Inflammation-Related Genes in Healthy Subjects: A Controlled Randomized Crossover Study. Hormone and Metabolic Research, 2014, 46, 789-793.	1.5	6

#	Article	IF	Citations
145	CCAAT/enhancer-binding protein Î´ (C/EBPÎ´) aggravates inflammation and bacterial dissemination during pneumococcal meningitis. Journal of Neuroinflammation, 2015, 12, 88.	7.2	6
146	Myeloid DNA methyltransferase3b deficiency aggravates pulmonary fibrosis by enhancing profibrotic macrophage activation. Respiratory Research, 2022, 23, .	3.6	6
147	Type I diabetes: a role for tissue factor in pancreatic islet transplantation?. Lancet, The, 2002, 360, 1999-2000.	13.7	5
148	Gene expression profile comparison of Barrett's esophagus epithelial cell cultures and biopsies. Ecological Management and Restoration, 2008, 21, 628-633.	0.4	5
149	Canonical Hedgehog signaling drives proangiogenic responses in endothelial cells. Cell Cycle, 2010, 9, 1678-1683.	2.6	5
150	Increased Mortality during Bleomycin-induced Pulmonary Fibrosis due to Low Endogenous Activated Protein C Levels. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1257-1259.	5.6	5
151	Type-I Protein-C Deficiency Caused by Disruption of a Hepatocyte Nuclear Factor (HNF)-6/HNF-1 Binding Site in the Human Protein-C Gene Promoter. Trends in Cardiovascular Medicine, 1999, 9, 82-85.	4.9	4
152	Concerted action of coagulation factors on cell survival. Journal of Thrombosis and Haemostasis, 2004, 2, 673-674.	3.8	4
153	Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation. Biomolecules, 2021, 11, 1079.	4.0	4
154	Protease activated receptor 2 in diabetic nephropathy: a double edged sword. American Journal of Translational Research (discontinued), 2017, 9, 4512-4520.	0.0	4
155	Macrophage C/EBPÎ´ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner. Biomedicines, 2022, 10, 219.	3.2	4
156	A mechanism for thrombinâ€dependent lung metastasis in patients with osteosarcoma. British Journal of Haematology, 2009, 145, 548-550.	2.5	3
157	Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity. Thrombosis Research, 2009, 123, 914-918.	1.7	3
158	Protease-Activated Receptor 2 Blocking Peptide Counteracts Endotoxin-Induced Inflammation and Coagulation and Ameliorates Renal Fibrin Deposition in a Rat Model of Acute Renal Failure. Shock, 2010, 33, 339.	2.1	3
159	Prophylactic plasma levels of the low molecular weight heparin nadroparin does not affect colon cancer tumor development in mouse liver. Thrombosis Research, 2010, 125, 235-238.	1.7	3
160	Experimental and clinical effects of anticoagulants on cancer progression. Thrombosis Research, 2010, 125, S77-S79.	1.7	3
161	Proteaseâ€activated receptorâ€1 impedes prostate and intestinal tumor progression in mice: comment. Journal of Thrombosis and Haemostasis, 2019, 17, 235-238.	3.8	3
162	CCAAT/enhancer binding protein delta (C/EBPÎ´) deficiency does not affect bleomycin-induced pulmonary fibrosis. Journal of Clinical and Translational Research, 0, , .	0.3	3

#	Article	IF	Citations
163	CCAAT/enhancer binding protein delta (C/EBPÎ´) deficiency does not affect bleomycin-induced pulmonary fibrosis. Journal of Clinical and Translational Research, 2018, 3, 358-365.	0.3	3
164	Functional Evolution of Tissue Factor, the Archetype of the Cytokine Receptor Family. Current Genomics, 2005, 6, 367-373.	1.6	2
165	Letter in response to 'Coagulation and fibrosis in chronic liver disease'. Gut, 2009, 58, 1565-1566.	12.1	2
166	PO-28 - Protein C levels are associated with mortality in patients with advanced cancer. Thrombosis Research, 2016, 140, S186-S187.	1.7	2
167	Proteaseâ€activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma. Molecular Oncology, 2021, 15, 3091-3108.	4.6	2
168	Unique distance- and DNA-turn-dependent interactions in the human protein C gene promoter confer submaximal transcriptional activity. Biochemical Journal, 1999, 340, 513.	3.7	1
169	OC-08 Effects of low-molecular-weight heparins on metastatic tumor development in animal models. Thrombosis Research, 2007, 120, S143-S144.	1.7	1
170	CCAAT/Enhancer-Binding Protein Î´. American Journal of Pathology, 2013, 182, 1459-1460.	3.8	1
171	<scp>CCAAT</scp>/enhancerâ€binding protein delta (C/<scp>EBP</scp>Î´) plays a minor role in renal host defense against uropathogenic <scp>E</scp>scherichia coli. Transplant Infectious Disease, 2013, 15, E119-21.	1.7	1
172	Detrimental role for CCAAT/enhancer binding protein Î´ in blood-borne brain infection. BMC Infectious Diseases, 2016, 16, 670.	2.9	1
173	Alveolar epithelial TET2 is not involved in the development of bleomycinâ€induced pulmonary fibrosis. FASEB Journal, 2021, 35, e21599.	0.5	1
174	Insights Into the Mechanism of Zymogen Protein C Protection Against Cancer Progression. Blood, 2012, 120, 3350-3350.	1.4	1
175	Novel human pathological mutations. Gene symbol: PROS1. Disease: Protein S deficiency. Human Genetics, 2010, 127, 121.	3.8	1
176	Editorial [Hot Topic: Understanding and Treatment of Diseases in the Haemostatic System (Guest) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	0
177	RNA-Based Gene Therapy for Haemophilia B. Current Genomics, 2005, 6, 401-404.	1.6	0
178	Inherited Coagulation Factor VII and X Deficiencies Associated with Severe Bleeding Diathesis: Molecular Genetics and Pathophysiology. Current Genomics, 2005, 6, 383-400.	1.6	0
179	Response to Comment on â€œTissue Factor-Dependent Chemokine Production Aggravates Experimental Colitisâ€. Molecular Medicine, 2011, 17, 1132-1132.	4.4	0
180	PAR-2 activation induces migration but not proliferation of pancreatic cancer cells. Thrombosis Research, 2012, 129, S191.	1.7	0

#	Article	IF	Citations
181	Thrombin induces pancreatic cancer cell survival during growth factor deprivation. Thrombosis Research, 2012, 129, S191.	1.7	0
182	A polymorphism in the gene for protein tyrosine phosphatase 1b is associated with altered lipid profile and myocardial infarction. Atherosclerosis, 2014, 235, e131.	0.8	0
183	Mendelian randomization in inflammatory conditions â€“ the exception rather than the rule?. Atherosclerosis, 2014, 235, e221-e222.	0.8	0
184	Authors' replyâ€”Re: Shi et al. Proteaseâ€activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. J Pathol 2014;234: 398â€“409. Journal of Pathology, 2015, 236, 130-130.	4.5	0
185	CCAAT/Enhancer Binding Protein Delta exerts tumor-supportive effects but is down-regulated in patient hepatocellular carcinoma. Journal of Hepatology, 2017, 66, S640.	3.7	0
186	Thrombin-mediated vasculogenic mimicry: important lessons to improve anticoagulant therapy of selected cancer patients. Signal Transduction and Targeted Therapy, 2020, 5, 253.	17.1	0
187	Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?. European Respiratory Journal, 2020, 55, 2000811.	6.7	0
188	Pivotal role of Proteaseâ€activated receptorâ€2 in bleomycinâ€induced pulmonary fibrosis. FASEB Journal, 2010, 24, 31.8.	0.5	0
189	Zymogen Protein C as a Novel Modulator of Cancer Progression In Murine Models. Blood, 2010, 116, 718-718.	1.4	0
190	The Role of Activated Protein C in Cancer. Blood, 2011, 118, SCI-18-SCI-18.	1.4	0
191	Abstract B48: Protease-activated receptor 2 in the microenvironment drives lymphangiogenesis and subsequent lymph metastasis in a murine pancreatic cancer model.. , 2012, , .		0
192	Abstract A78: PAR-2 activation with ATP facilitation induces migration but not proliferation of pancreatic cancer cells.. , 2012, , .		0
193	The anti-coagulants ASIS or APC do not protect against renal ischemia/ reperfusion injury. ScienceOpen Research, 0, , .	0.6	0
194	Detrimental role for matrix metalloprotease-1 in the pathogenesis of pulmonary fibrosis. , 2017, , .		0
195	Abstract 5225: PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer. , 2018, , .		0
196	In silico tissue factor analysis: a bit-to-bit comparison. Thrombosis and Haemostasis, 2003, 89, 592-3.	3.4	0